Acasti pharma to host kol event on gtx-104: a potential new treatment standard for rare and life-threatening aneurysmal subarachnoid hemorrhage (asah)

Princeton, n.j., oct. 04, 2023 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced that it will host a virtual kol event titled gtx-104: a potential new treatment standard for rare and life-threatening asah on wednesday, october 11, 2023 at 2:00pm et.
ACST Ratings Summary
ACST Quant Ranking